Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520224 | 0.84 | S1PR3 (0.53) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL5575578 | 0.84 | S1PR3 (0.53) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL4277192 | 0.82 | S1PR3 (0.53) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL31750821 | 0.82 | S1PR3 (0.50) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL4289099 | 0.82 | S1PR3 (0.53) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL999536 | 0.82 | S1PR3 (0.53) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL1525463 | 0.81 | S1PR3 (0.52) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL1525552 | 0.81 | S1PR3 (0.52) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL1525465 | 0.81 | S1PR3 (0.52) | CTSSCTSKS1PR3PPARGPPARA | |
| SCHEMBL16171643 | 0.80 | TRPA1 (0.50) | CTSSCTSKS1PR3PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| CN-102015661-A | Arylpyrazinone derivative insulin secretion stimulators, methods for obtaining them and their use for the treatment of diabetes | MERCK PATENT GMBH | 2011-04-13 | — | — | CN | disclosed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2268624-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | IAPP, GPR119, GLP1R | CTSS 1688/4885CTSK 498/4885S1PR3 3100/4885 |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GLP1R, GPR119, IAPP | CTSS 1679/4885CTSK 1512/4885S1PR3 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.